Key result
The use of desogestrel-containing monophasic oral contraceptives was associated with lower levels of lipoprotein (a) compared to triphasic/levonorgestrel formulations or non-users (P=0.005).
Why the study?
Does the use of oral contraceptives influence lipoprotein (a) and other coronary heart disease risk factors in young women?
Cohort (n=559)
Does the use of oral contraceptives influence lipoprotein (a) and other coronary heart disease risk factors in young women?
p-value: p=0.005
Desogestrel-containing oral contraceptives are associated with lower lipoprotein (a) levels in young, non-smoking women, though they also increase other lipid parameters and systolic blood pressure.
No takes yet. Share an insight, caveat, or question.
Desogestrel OC use was associated with lower Lp(a) in nonsmoking women; leaves open net CV effects pending prospective trials.
Porkka et al. (1995) reported a cohort. Oral contraceptives (desogestrel-containing monophasic preparations) vs. Triphasic/levonorgestrel formulations or non-users was evaluated on Lipoprotein (a) levels (p=0.005). The use of desogestrel-containing monophasic oral contraceptives was associated with lower levels of lipoprotein (a) compared to triphasic/levonorgestrel formulations or non-users (P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: